Hydroxyurea Associated Cutaneous Lesions: A Case Report

  • Viktor Simeonovski Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Hristina Breshkovska University Clinic for Plastic and Reconstructive Surgery, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Silvija Duma University Clinic for Dermatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Ivana Dohcheva-Karajovanov University Clinic for Dermatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Katerina Damevska University Clinic for Dermatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
  • Suzana Nikolovska University Clinic for Dermatology, Faculty of Medicine, Ss Cyril and Methodius University of Skopje, Skopje
Keywords: Hydroxyurea therapy, Cutaneous side effects, Leg ulcer, Basal cell carcinoma

Abstract

BACKGROUND: Hydroxyurea (HU) is an antimetabolite agent that interferes with the S-phase of cellular replication and inhibits DNA synthesis, with little or no effect on RNA or protein synthesis. It is used in the treatment of many myeloproliferative disorders (MD) and is particularly a first line treatment drug for intermediate to high-risk essential thrombocythemia. Although safe and very well tolerated by the patients suffering from MD, there have been numerous reports of a broad palette of cutaneous side effects associated with prolonged intake of the medication. These may include classical symptoms such as xerosis, diffuse hyperpigmentation, brown-nail discolouration, stomatitis and scaling of the face, hands, and feet or more serious side effects such as actinic keratosis lesions, leg ulcers and multiple skin carcinomas.

CASE REPORT: We report a case of a 52-year-old man, on long-term therapy with HU for essential thrombocytosis, with several concurrent skin lesions. Despite the perennial use of HU, the cutaneous changes were neglected. The local dermatological examination revealed oval perimalleolar ulcer on the right leg, with dimensions 6 x 4 cm, clearly demarcated from the surroundings with regular margins, periulcerous erythema, with very deep and highly fibrinous bed of the ulcer, positive for bacterial infection. The ulcer was treated with topical wound therapy with alginate and parenteral antibiotics. The extended dermatological screening also showed two nummular lesions in the right brachial region, presenting as erythematous papules with sharp margins from the surrounding skin, gritty desquamation and dotted hyperpigmentations inside the lesion. Further dermoscopy and biopsy investigations confirmed a diagnosis of basal cell carcinoma. Nasal actinic keratosis was also noted. The patient was advised for discontinuing or substituting the HU therapy.

CONCLUSION: We present this case to draw attention to the various cutaneous side effects that occur with perennial HU use and suggest an obligatory reference to a dermatological consult.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Best PJ, Petitt RM. Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin Proc. 1998; 73(10):961-3. https://doi.org/10.4065/73.10.961 PMid:9787746

Sirieix ME, Debure C, Baudot N et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol. 1999; 135(7):818-820. https://doi.org/10.1001/archderm.135.7.818 PMid:10411157

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, riskâ€stratification and management. Am J Hematol. 90:162-173.

Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer Journal. 2018; 8(1):3. https://doi.org/10.1038/s41408-017-0042-7 PMid:29321547 PMCid:PMC5802495

Randi ML, Ruzzon E, Tezza F et al. Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets. 2005; 16(3-4):181-4. https://doi.org/10.1080/09537100400020179 PMid:16011962

Antar A, Ishak RS, Otrock ZK. et al. Successful treatment of hydroxyurea-associated chronic leg ulcers associated with squamous cell carcinoma. Hematol Oncol Stem Cell Ther. 2014; 7(4):166-9. https://doi.org/10.1016/j.hemonc.2014.09.008 PMid:25467031

Guillot B, Bessis D, Dereure O. Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf. 2004; 3(6):579-87. https://doi.org/10.1517/14740338.3.6.579 PMid:15500416

Hwang S-W, Hong S-K, Kim S-H, Seo J-K, Lee D, Sung H-S. A Hydroxyurea-induced Leg Ulcer. Annals of Dermatology. 2009; 21(1):39-41. https://doi.org/10.5021/ad.2009.21.1.39 PMid:20548853 PMCid:PMC2883366

Ravandi-Kashani F, Cortes J, Cohen P et al. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma. 1999; 35(1-2):109-18. https://doi.org/10.3109/10428199909145710 PMid:10512168

Stahl LR, Silber R. Vasculitic leg ulcers in chronic myelogenous leukemia. Am J Hematol. 1985; 78: 869-72. https://doi.org/10.1016/0002-9343(85)90297-9

Fioramonti P1, Fino P, Parisi P et al. A case of hydroxyurea-induced leg ulcer after definitive treatment suspension in a patient affected by thrombocythemia: effectiveness of a new collagenase. In Vivo. 2012; 26(6):1053-6.

Hoff NP, Akanay-Diesel S, Pippirs U et al. Cutaneous side effects of hydroxyurea treatment for polycythemia vera. Hautarzt. 2009; 60(10):783-7. https://doi.org/10.1007/s00105-009-1844-8 PMid:19756436

Boneberger S, Rupec RA, Ruzicka T. Ulcers following therapy with hydroxyurea. Three case reports and review of the literature. Hautarzt. 2010; 61(7):598-602. https://doi.org/10.1007/s00105-009-1794-1 PMid:19763519

Saravu K, Velappan P, Lakshmi N, Shastry BA, Thomas J. Hydroxyurea Induced Perimalleolar Ulcers. Journal of Korean Medical Science. 2006; 21(1):177-179. https://doi.org/10.3346/jkms.2006.21.1.177 PMid:16479088 PMCid:PMC2733971

Published
2018-08-19
How to Cite
1.
Simeonovski V, Breshkovska H, Duma S, Dohcheva-Karajovanov I, Damevska K, Nikolovska S. Hydroxyurea Associated Cutaneous Lesions: A Case Report. Open Access Maced J Med Sci [Internet]. 2018Aug.19 [cited 2020Nov.29];6(8):1458-61. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2018.320
Section
C- Case Reports